Reza Zadno, PhD
PRESIDENT & CHIEF EXECUTIVE OFFICER
Dr. Zadno has served as PROCEPT BioRobotics President and Chief Executive Officer and a member of the board of directors since February 2020. Prior to joining PROCEPT BioRobotics Dr. Zadno served as President and Chief Executive Officer of Avedro, Inc., an ophthalmology company that developed a proprietary Corneal Remodeling Platform Technology. During his time at Avedro, Inc. from September 2016 to November 2020, he led the company through an IPO and rapid commercialization, and ultimately an acquisition by Glaukos; he also served as a member of the board of directors at Avedro. Prior to Avedro, Dr. Zadno served as Innovation Advisor and Venture Partner at InterWest Partners, a venture capital firm, from January 2012 to January 2018. Dr. Zadno has also served on the boards of directors of Invuity, Inc. from January 2013 to June 2017, where he was a member of the audit committee, and Carbylan Therapeutics, Inc. from June 2013 to November 2016, where he was a member of the audit committee. Dr. Zadno also served on the Board of a number of additional private companies. Dr. Zadno also co-founded PercuSurge, a maker of distal protection devices used in treating occluded carotid arteries and saphenous vein grafts, which was acquired by Medtronic. Dr. Zadno received both a Ph.D. and an M.Sc. in Mechanical Properties of Materials from École Nationale Supérieure des Mines de Paris.
Frederic Moll, M.D.
CHAIRMAN OF THE BOARD
Dr. Moll is the founder, Chairman and CEO of Auris Surgical Robotics. Prior to Auris he was co-founder of Hansen Medical, Restoration Robotics and founder and first CEO of Intuitive Surgical, the world leader in surgical robotics, and a major player in urology. Dr. Moll was a co-founder of Origin Medsystems, and served as the Medical Director of Guidant's Surgical Device Division. Early in his career he founded Endotherapeutics, a pioneering company in laparoscopic surgical technology. Dr. Moll holds a B.A. degree from the University of California at Berkeley, an M.S. degree in management from Stanford University, and an M.D. degree from the University of Washington.
Antal Desai
DIRECTOR
Mr. Desai is a partner at CPMG, Inc. CPMG is an investment firm that employs a concentrated, value-oriented approach to investing in publicly traded and private operating companies. Prior to joining CPMG’s predecessor, Cardinal Investment Company, Mr. Desai worked as an analyst at WhiteHorse Capital Partners, L.P. He currently serves on the Board of Directors of PROCEPT BioRobotics Corporation, Theatro Labs, Inc., ESN Venture Holdings LLC, Lifeblue Incorporated, and Travel Research Advisors LLC. Mr. Desai holds a B.S. and an M.B.A. from The Wharton School at the University of Pennsylvania.
Amy Dodrill
DIRECTOR
Ms. Dodrill has served healthcare and technology companies for more than 20 years and is currently the President of Global Surgical Solutions at Hillrom Holdings, Inc. ("Hillrom"). At Hillrom, she has been responsible for achieving enhanced operational effectiveness, market expansion and market share growth. Prior roles at Hillrom include Vice President and General Manager, US Surgical Division, Vice President and General Manager of Trumpf Medical Surgical Solutions NA and Area Vice President & General Manager. Earlier in her career, she served as a Vice President, Commercial Operations at DynaVox, and prior to that was a Regional Vice President at GE Healthcare. Ms. Dodrill holds a Bachelor of Science in Biomedical Engineering from Johns Hopkins University and completed a fellowship in Physiology at Wake Forest University.
Colby Wood
DIRECTOR
Mr. Wood is a Portfolio Manager and Research Analyst for Oechsle International Advisors in London where he is responsible for medical technology investments globally. Prior to this current position, he was with Freeman & Company, a boutique M&A advisory firm focused on the financial services industry. Earlier in his career Mr. Wood was actively involved as an investor, asset gatherer and business development executive for early stage companies in financial services and medical technology sectors. Mr. Wood holds a B.A. from the University of Delaware and an MBA in Finance and Entrepreneurship from the F.W. Olin Graduate of Business at Babson College.
Taylor Harris
CHAIR OF THE AUDIT COMMITTEE
Mr. Harris most recently served as the Chief Financial Officer of MyoKardia, Inc., a clinical-stage biopharmaceutical company discovering and developing therapies for the treatment of serious cardiovascular diseases. MyoKardia was acquired in November 2020 by Bristol Myers Squibb for $13.1 billion. Prior to joining MyoKardia, Mr. Harris served as Chief Financial Officer of Zeltiq Aesthetics, Inc., until that company’s acquisition by Allergan plc. Prior to Zeltiq, Mr. Harris served as Chief Financial Officer at Thoratec Corporation, until that company’s acquisition by St. Jude Medical, Inc. Prior to joining Thoratec, Mr. Harris worked at JPMorgan Chase & Co. for over a decade in several capacities, including as a Vice President in the firm's Healthcare Investment Banking and Equity Research departments. Mr. Harris holds a Bachelor of Arts in Physics and Economics from the University of North Carolina at Chapel Hill, where he studied as a Morehead-Cain Scholar.
Thomas Krummel, M.D.
DIRECTOR
Dr. Krummel is the Surgeon-in-Chief at Lucile Packard Children’s Hospital and Chairman of the Surgery Department at the Stanford University School of Medicine, He is the founder of the Surgical Innovation Program at Stanford, and Co-Director of the Stanford Biodesign Program which teaches innovation and implementation of new surgical technologies. The program has spawned 35 start-ups which have received more than $300 million in follow-on financing. Dr. Krummel has lectured throughout the world and is author or co-author of over 300 publications, chapters, abstracts and books. He is on the board of the Fogarty Innovation Institute and has served on the board of directors or scientific advisory boards of 15 medical device start-ups.
Elisabeth Sandoval
DIRECTOR

Ms. Sandoval currently serves as a consultant to the pharmaceutical industry and is a member of the board of directors of Intersect ENT, Inc., Satsuma Pharmaceuticals, Inc. and Vyne Therapeutics, Inc. She is also on the Board of privately held Alastin Skincare. Ms. Sandoval previously served as the Chief Commercial Officer and Executive Vice President of Corporate Strategy at Alder Biopharmaceuticals. She was Chief Commercial Officer for Kythera Biopharmaceuticals and spent over 20 years at Allergan in a variety of commercial leadership roles of increasing responsibility. Ms. Sandoval holds a B.S. in Biology from University of California at Irvine and an M.B.A. from Pepperdine University, The George L. Graziadio School of Business and Management.